
SMC approve pembroliziumab for adjuvant treatment for resected stage 2B or 2C melanoma
Melanoma Focus are delighted with the news that the SMC have approved the recommendation of pembrolizumab as an option for the adjuvant treatment of completely resected stage 2B or 2C melanoma in people 12 years and over in Scotland.
Clinical Advances
Read more